KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Repayments: 2020-2021

Historic Long-Term Debt Repayments for AbCellera Biologics (ABCL) over the last 1 years, with Jun 2021 value amounting to $107,000.

  • AbCellera Biologics' Long-Term Debt Repayments rose 272.58% to $107,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $19.8 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2021, which is 90.86% down from last year.
  • Latest data reveals that AbCellera Biologics reported Long-Term Debt Repayments of $107,000 as of Q2 2021, which was down 93.76% from $1.7 million recorded in Q1 2021.
  • Over the past 5 years, AbCellera Biologics' Long-Term Debt Repayments peaked at $15.0 million during Q3 2020, and registered a low of -$62,000 during Q2 2020.
  • In the last 2 years, AbCellera Biologics' Long-Term Debt Repayments had a median value of $1.9 million in 2020 and averaged $3.6 million.
  • The largest annual percentage gain for AbCellera Biologics' Long-Term Debt Repayments in the last 5 years was 272.58% (2021), contrasted with its biggest fall of 15.59% (2021).
  • AbCellera Biologics' Long-Term Debt Repayments (Quarterly) stood at $3.0 million in 2020, then surged by 272.58% to $107,000 in 2021.
  • Its Long-Term Debt Repayments stands at $107,000 for Q2 2021, versus $1.7 million for Q1 2021 and $3.0 million for Q4 2020.